BEACON-IPF Clinical Trial Overview: Investigating the slowing or halting of idiopathic pulmonary fibrosis

Get an overview of Pliant Therapeutics BEACON-IPF global clinical trial which aims to find out whether bexotegrast slows down or halts idiopathic pulmonary fibrosis disease progression over a 52-week treatment period by reducing scar formation (fibrosis) of the lungs.

Learn about previous clinical trial results, how to participate if you have idiopathic pulmonary fibrosis, and what to expect.